IP Library Granted Patent US 7,632,822
Granted Patent B2
US 7,632,822 · App. 11/173,938 · Granted Dec 15, 2009

Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,632,822
App. No.
11/173,938
Granted
Dec 15, 2009
Kind
B2
Abstract

The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end.

Claims (8)

1. An immunostimulatory oligonucleotide having the structure 5′-CTGTCG 2 TTCTC-X-CTCTTG 2 CTGTC-5′; wherein X is a glycerol linker and G 2 is arabinoguanosine.

2. A composition comprising the oligonucleotide according to claim 1 and a physiologically acceptable carrier.

3. The composition according to claim 2 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

4. A composition comprising the oligonucleotide according to claim 1 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

5. A method for generating an immune response in a mammal, the method comprising administering to the mammal an immunostimulatory oligonucleotide having the structure 5′-CTGTCG 2 TTCTC-X-CTCTTG 2 CTGTC-5′;

wherein X is a glycerol linker and G 2 is arabinoguanosine.

6. The method according to claim 5 , wherein the route of administration is selected from the group consisting of parental, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.

7. The method according to claim 5 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 30, 2005
From: HYBRIDON, INC
To: IDERA PHARMACEUTICALS, INC
Reel/Frame 017240/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2005
From: AGRAWAL, SUDHIR; BHAGAT, LAKSHMI; YU, DONG; KANDIMALLA, EKAMBAR
To: HYBRIDON, INC.
Reel/Frame 016994/0742 →